Get started
Author

Norihisa Ohtake

Institution: Tosoh (Japan)
ORCID: 0000-0003-2339-4025
Observed ORCID: 0000-0003-2339-4025
OpenAlex ID: A5059740179
Secretome-Based Identification of TFPI2, A Novel Serum Biomarker for Detection of Ovarian Clear Cell Adenocarcinoma
2013 · Noriaki Arakawa, Etsuko Miyagi, et al. · Journal of Proteome Research · 78
Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination
2022 · Hideaki Kato, Kei Miyakawa, et al. · Vaccine · 41
PDF
Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma
2016 · Noriaki Arakawa, Hiroshi Kobayashi, et al. · PLoS ONE · 36
PDF
Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles
2020 · Kei Miyakawa, Sundararaj Stanleyraj Jeremiah, et al. · Journal of Molecular Cell Biology · 35
PDF
Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix
2021 · Yukihide Ota, Shiro Koizume, et al. · Oncology Reports · 28
PDF
Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay
2021 · Hideaki Kato, Kei Miyakawa, et al. · Journal of Infection and Chemotherapy · 22
PDF
Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors
2021 · Atsushi Goto, Hirofumi Go, et al. · Frontiers in Microbiology · 18
PDF
Development of an Automated Chemiluminescence Assay System for Quantitative Measurement of Multiple Anti-SARS-CoV-2 Antibodies
2021 · Sousuke Kubo, Norihisa Ohtake, et al. · Frontiers in Microbiology · 18
PDF
Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection
2021 · Kei Miyakawa, Sousuke Kubo, et al. · Open Forum Infectious Diseases · 10
PDF
Enhancement of Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 by a Third Dose of BNT162b2 Vaccine in Japanese Healthcare Workers
2022 · Kei Miyakawa, Hideaki Kato, et al. · The Journal of Infectious Diseases · 9
PDF
Tissue factor pathway inhibitor-2 inhibits integrin β1 activation and focal adhesion formation and suppresses peritoneal ovarian cancer dissemination in mice
2024 · Yukihide Ota, Mari Uomoto, et al. · Biochemical and Biophysical Research Communications · 8
Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study
2024 · Mari Uomoto, Yukihide Ota, et al. · BMC Cancer · 6
PDF
Prediction models for neutralization activity against emerging SARS-CoV-2 variants: A cross-sectional study
2023 · Atsushi Goto, Kei Miyakawa, et al. · Frontiers in Microbiology · 5
Analysis of humoral immunity against emerging SARS-CoV-2 variants: a population-based prevalence study in Yokohama, Japan
2022 · Atsushi Goto, Kei Miyakawa, et al. · medRxiv
PDF
Abstract 228: Identification of a novel biomarker to predict castration-resistant prostate cancer (CRPC) by the proteome analysis
2017 · Hiroji Uemura, Noriaki Arakawa, et al. · Cancer Research
Novel biomarker of specific castration-resistant prostate cancer (CRPC) by exploring the proteome analysis.
2017 · Hiroji Uemura, Noriaki Arakawa, et al. · Journal of Clinical Oncology
Works count: 16
Citation count: 314
H-index: 9
I10-index: 9
Year
Topic
Type